Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.77 |
| ▸ | PPARG | P37231 | 12/20 | 0.77 |
| ▸ | RXRA | P19793 | 10/20 | 0.77 |
| ▸ | RXRB | P28702 | 9/20 | 0.77 |
| ▸ | RXRG | P48443 | 7/20 | 0.77 |
| ▸ | PPARD | Q03181 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.73 |
| ▸ | PTGES | O14684 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirinixic Acid SCHEMBL29370056 | 0.87 | PPARA (1.00) | PPARAPPARGRXRARXRBRXRG | |
| Pirinixic Acid SCHEMBL293161 | 0.87 | PPARA (1.00) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11492690 | 0.87 | PPARA (0.76) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11833234 | 0.86 | PPARA (0.82) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11483023 | 0.85 | PPARA (0.77) | PPARAPPARGRXRARXRBRXRG | |
| Pirinixic Acid SCHEMBL6563348 | 0.85 | PPARA (0.80) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL6563962 | 0.84 | PPARA (0.78) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11491689 | 0.84 | PPARA (0.74) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11492445 | 0.83 | PPARA (0.73) | PPARAPPARGRXRARXRBRXRG | |
| SCHEMBL11484199 | 0.83 | PPARA (0.73) | PPARAPPARGRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399426-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | Active Pass Pharmaceuticals, Inc. (CA) | 2004-03-24 | — | — | EP | disclosed |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-10-09 | — | — | US | disclosed |
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2002100836-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
| US-3940394-A | ANTILIPEMIC | SANTILLI ARTHUR A | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | PPARA 2/4885PPARG 3/4885RXRA 79/4885 |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | PPARA 2/4885PPARG 3/4885RXRA 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.